Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence
The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with be...
Gespeichert in:
| Veröffentlicht in: | Addictive behaviors 2004-08, Vol.29 (6), p.1059-1065 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1065 |
|---|---|
| container_issue | 6 |
| container_start_page | 1059 |
| container_title | Addictive behaviors |
| container_volume | 29 |
| creator | Vorma, Helena Naukkarinen, Hannu Sarna, Seppo Kuoppasalmi, Kimmo |
| description | The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with benzodiazepine dependence (
DSM-III-R) who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were initially assessed by Symptom Checklist-90 (SCL-90), visual analogue scales (VASs), and the Health-Related Quality of Life battery (HRQOL). The assessments were repeated after treatment ended and again after a follow-up averaging 11 months. During the study, all measurements for the participants with clinically significant (over 50%) benzodiazepine-dose decreases improved more than those for the participants with smaller decreases, and differences in the HRQOL energy/vitality, home management, and life satisfaction scores were significant. Our data indicate that in participants with complicated benzodiazepine dependence, clinically significant dose decreases are associated with improvements in their self-rated quality of life. |
| doi_str_mv | 10.1016/j.addbeh.2004.03.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_32693704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306460304000772</els_id><sourcerecordid>32693704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-562597734a80e594c35de7c0693b41a8d1b5f484d56ba7eaf98ae3992fb6c18f3</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhoMoznX0H4gEF-5akyZN040gg18w4EJdh9PkhMmlTTtJOsO9v95e7wXBhaucxXPeE96HkNec1Zxx9X5fg3MD3tUNY7JmomZMPCE7rjtRKdF0T8mOCaYqqZi4Ii9y3jPGm66Vz8kVbxuhNOt25PjjMC1lnmjGB0yhHChER-9XGE_z7OkYPFLwBRMdMB5nF-CIS4hIH0O5cwkeYaQlIZQJY6Eh0gVSCTYsEEv-A1E7T8sYLBR01OGC0WG0-JI88zBmfHV5r8mvz59-3nytbr9_-Xbz8baykqtStapp-64TEjTDtpdWtA47y1QvBslBOz60XmrpWjVAh-B7DSj6vvGDslx7cU3enXOXNN-vmIuZQrY4jhBxXrMRzRbVMbmBb_8B9_Oa4vY303Ddi600vUHyDNk055zQmyWFCdLBcGZOYszenMWYkxjDhNnEbGtvLtnrMKH7u3QxsQEfzgBuVTwETCbbcKrJhYS2GDeH_1_4DZWNouE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218935238</pqid></control><display><type>article</type><title>Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Vorma, Helena ; Naukkarinen, Hannu ; Sarna, Seppo ; Kuoppasalmi, Kimmo</creator><creatorcontrib>Vorma, Helena ; Naukkarinen, Hannu ; Sarna, Seppo ; Kuoppasalmi, Kimmo</creatorcontrib><description>The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with benzodiazepine dependence (
DSM-III-R) who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were initially assessed by Symptom Checklist-90 (SCL-90), visual analogue scales (VASs), and the Health-Related Quality of Life battery (HRQOL). The assessments were repeated after treatment ended and again after a follow-up averaging 11 months. During the study, all measurements for the participants with clinically significant (over 50%) benzodiazepine-dose decreases improved more than those for the participants with smaller decreases, and differences in the HRQOL energy/vitality, home management, and life satisfaction scores were significant. Our data indicate that in participants with complicated benzodiazepine dependence, clinically significant dose decreases are associated with improvements in their self-rated quality of life.</description><identifier>ISSN: 0306-4603</identifier><identifier>EISSN: 1873-6327</identifier><identifier>DOI: 10.1016/j.addbeh.2004.03.003</identifier><identifier>PMID: 15236807</identifier><identifier>CODEN: ADBED9</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Anti-Anxiety Agents - administration & dosage ; Benzodiazepines ; Benzodiazepines - administration & dosage ; Drug dependency ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Psychometrics ; Quality of Life ; Substance abuse treatment ; Substance Withdrawal Syndrome - rehabilitation ; Substance-Related Disorders - rehabilitation ; Substance-Related Disorders - therapy ; Symptoms ; Treatment ; Treatment Outcome</subject><ispartof>Addictive behaviors, 2004-08, Vol.29 (6), p.1059-1065</ispartof><rights>2003 Elsevier Ltd</rights><rights>Copyright Pergamon Press Inc. Aug 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-562597734a80e594c35de7c0693b41a8d1b5f484d56ba7eaf98ae3992fb6c18f3</citedby><cites>FETCH-LOGICAL-c416t-562597734a80e594c35de7c0693b41a8d1b5f484d56ba7eaf98ae3992fb6c18f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.addbeh.2004.03.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15236807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vorma, Helena</creatorcontrib><creatorcontrib>Naukkarinen, Hannu</creatorcontrib><creatorcontrib>Sarna, Seppo</creatorcontrib><creatorcontrib>Kuoppasalmi, Kimmo</creatorcontrib><title>Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence</title><title>Addictive behaviors</title><addtitle>Addict Behav</addtitle><description>The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with benzodiazepine dependence (
DSM-III-R) who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were initially assessed by Symptom Checklist-90 (SCL-90), visual analogue scales (VASs), and the Health-Related Quality of Life battery (HRQOL). The assessments were repeated after treatment ended and again after a follow-up averaging 11 months. During the study, all measurements for the participants with clinically significant (over 50%) benzodiazepine-dose decreases improved more than those for the participants with smaller decreases, and differences in the HRQOL energy/vitality, home management, and life satisfaction scores were significant. Our data indicate that in participants with complicated benzodiazepine dependence, clinically significant dose decreases are associated with improvements in their self-rated quality of life.</description><subject>Adult</subject><subject>Anti-Anxiety Agents - administration & dosage</subject><subject>Benzodiazepines</subject><subject>Benzodiazepines - administration & dosage</subject><subject>Drug dependency</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psychometrics</subject><subject>Quality of Life</subject><subject>Substance abuse treatment</subject><subject>Substance Withdrawal Syndrome - rehabilitation</subject><subject>Substance-Related Disorders - rehabilitation</subject><subject>Substance-Related Disorders - therapy</subject><subject>Symptoms</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>0306-4603</issn><issn>1873-6327</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhoMoznX0H4gEF-5akyZN040gg18w4EJdh9PkhMmlTTtJOsO9v95e7wXBhaucxXPeE96HkNec1Zxx9X5fg3MD3tUNY7JmomZMPCE7rjtRKdF0T8mOCaYqqZi4Ii9y3jPGm66Vz8kVbxuhNOt25PjjMC1lnmjGB0yhHChER-9XGE_z7OkYPFLwBRMdMB5nF-CIS4hIH0O5cwkeYaQlIZQJY6Eh0gVSCTYsEEv-A1E7T8sYLBR01OGC0WG0-JI88zBmfHV5r8mvz59-3nytbr9_-Xbz8baykqtStapp-64TEjTDtpdWtA47y1QvBslBOz60XmrpWjVAh-B7DSj6vvGDslx7cU3enXOXNN-vmIuZQrY4jhBxXrMRzRbVMbmBb_8B9_Oa4vY303Ddi600vUHyDNk055zQmyWFCdLBcGZOYszenMWYkxjDhNnEbGtvLtnrMKH7u3QxsQEfzgBuVTwETCbbcKrJhYS2GDeH_1_4DZWNouE</recordid><startdate>20040801</startdate><enddate>20040801</enddate><creator>Vorma, Helena</creator><creator>Naukkarinen, Hannu</creator><creator>Sarna, Seppo</creator><creator>Kuoppasalmi, Kimmo</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope><scope>K7.</scope><scope>K9.</scope><scope>7TA</scope><scope>8FD</scope><scope>JG9</scope></search><sort><creationdate>20040801</creationdate><title>Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence</title><author>Vorma, Helena ; Naukkarinen, Hannu ; Sarna, Seppo ; Kuoppasalmi, Kimmo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-562597734a80e594c35de7c0693b41a8d1b5f484d56ba7eaf98ae3992fb6c18f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anti-Anxiety Agents - administration & dosage</topic><topic>Benzodiazepines</topic><topic>Benzodiazepines - administration & dosage</topic><topic>Drug dependency</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psychometrics</topic><topic>Quality of Life</topic><topic>Substance abuse treatment</topic><topic>Substance Withdrawal Syndrome - rehabilitation</topic><topic>Substance-Related Disorders - rehabilitation</topic><topic>Substance-Related Disorders - therapy</topic><topic>Symptoms</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vorma, Helena</creatorcontrib><creatorcontrib>Naukkarinen, Hannu</creatorcontrib><creatorcontrib>Sarna, Seppo</creatorcontrib><creatorcontrib>Kuoppasalmi, Kimmo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Business File</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><jtitle>Addictive behaviors</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vorma, Helena</au><au>Naukkarinen, Hannu</au><au>Sarna, Seppo</au><au>Kuoppasalmi, Kimmo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence</atitle><jtitle>Addictive behaviors</jtitle><addtitle>Addict Behav</addtitle><date>2004-08-01</date><risdate>2004</risdate><volume>29</volume><issue>6</issue><spage>1059</spage><epage>1065</epage><pages>1059-1065</pages><issn>0306-4603</issn><eissn>1873-6327</eissn><coden>ADBED9</coden><abstract>The aims of the present study were to assess changes in psychopathology and quality of life after withdrawal treatment in participants with benzodiazepine dependence that was in most cases complicated by harmful and hazardous alcohol use or high benzodiazepine doses. Seventy-six participants with benzodiazepine dependence (
DSM-III-R) who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were initially assessed by Symptom Checklist-90 (SCL-90), visual analogue scales (VASs), and the Health-Related Quality of Life battery (HRQOL). The assessments were repeated after treatment ended and again after a follow-up averaging 11 months. During the study, all measurements for the participants with clinically significant (over 50%) benzodiazepine-dose decreases improved more than those for the participants with smaller decreases, and differences in the HRQOL energy/vitality, home management, and life satisfaction scores were significant. Our data indicate that in participants with complicated benzodiazepine dependence, clinically significant dose decreases are associated with improvements in their self-rated quality of life.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15236807</pmid><doi>10.1016/j.addbeh.2004.03.003</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4603 |
| ispartof | Addictive behaviors, 2004-08, Vol.29 (6), p.1059-1065 |
| issn | 0306-4603 1873-6327 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_32693704 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Anti-Anxiety Agents - administration & dosage Benzodiazepines Benzodiazepines - administration & dosage Drug dependency Female Follow-Up Studies Humans Male Middle Aged Psychometrics Quality of Life Substance abuse treatment Substance Withdrawal Syndrome - rehabilitation Substance-Related Disorders - rehabilitation Substance-Related Disorders - therapy Symptoms Treatment Treatment Outcome |
| title | Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A47%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptom%20severity%20and%20quality%20of%20life%20after%20benzodiazepine%20withdrawal%20treatment%20in%20participants%20with%20complicated%20dependence&rft.jtitle=Addictive%20behaviors&rft.au=Vorma,%20Helena&rft.date=2004-08-01&rft.volume=29&rft.issue=6&rft.spage=1059&rft.epage=1065&rft.pages=1059-1065&rft.issn=0306-4603&rft.eissn=1873-6327&rft.coden=ADBED9&rft_id=info:doi/10.1016/j.addbeh.2004.03.003&rft_dat=%3Cproquest_cross%3E32693704%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218935238&rft_id=info:pmid/15236807&rft_els_id=S0306460304000772&rfr_iscdi=true |